Latest Revenue Growth News

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.

The a2 Milk Company has raised its FY26 revenue guidance, citing stronger-than-expected performance in key product categories and favourable currency movements. The company anticipates solid earnings growth and robust cash flow conversion.

Tasmea Limited reported a stellar FY25 with strong revenue and profit growth, bolstered by strategic acquisitions and a robust dividend payout. The company signals continued momentum with a new acquisition announcement and targets ASX300 inclusion in 2026.

Schaffer Corporation delivered solid FY25 results with revenue growth and record property valuations, but the Jaguar Land Rover cyberattack clouds the near-term outlook for its Automotive Leather division.

Experience Co Limited reported a strong FY25 with record revenue and earnings growth, driven by its Skydiving and Adventure Experiences segments. The company is advancing organic growth and acquisitions while maintaining disciplined capital management heading into FY26.

Stakk Limited has landed a pivotal 3-year contract with U.S. fintech giant SoFi, significantly boosting its annual recurring revenue projections beyond $8 million. This deal highlights Stakk’s growing footprint in embedded finance across major international brands.

Nufarm Limited posted a $165.3 million statutory loss for FY25, driven by significant restructuring charges and omega-3 price declines, while announcing a CEO transition effective January 2026.

EML Payments has affirmed its FY26 underlying EBITDA guidance of A$58-63 million following a solid Q1 trading update, underpinned by a growing new program pipeline and operational efficiencies.

OMG Group has inked a five-year exclusive distribution agreement with SANDAI, a premium Japanese matcha producer, positioning itself to capture significant growth in Australia’s expanding matcha market.

Cyclopharm Limited reaffirms its ambitious target of 250–300 US Technegas installations by late 2026, driven by FDA approval, CMS reimbursement, and a growing pipeline of healthcare sites. The company reports record half-year revenue growth, signaling strong momentum in the expanding lung imaging market.